论文部分内容阅读
目的观察莫沙必利联合小剂量多塞平治疗餐后不适综合征(post prandial distress syndrome,PDS)型功能性消化不良(type PDS functional dyspepsia,PDS-FD)的临床效果。方法选取2015年6月—2016年6月接受治疗的PDS-FD患者88例,随机分为观察组与对照组各44例,对照组单纯给予莫沙必利治疗,观察组予以莫沙必利复合小剂量多塞平治疗,均治疗4周。治疗后对两组症状进行评分;治疗前后用汉密尔顿焦虑量表(Hamilton anxiety scale,HAMA)与汉密尔顿抑郁量表(Hamilton’s depression scale,HAMD)评价焦虑抑郁程度;记录两组治疗期间失眠、头晕、皮疹以及腹泻等不良反应发生情况。计量资料比较用t检验,计数量资料比较用χ2检验,P<0.05为差异有统计学意义。结果治疗后观察组餐后嗳气、上腹灼烧感、餐后饱胀以及上腹痛积分[(0.42±0.02)、(0.41±0.01)、(0.15±0.06)、(0.39±0.02)分]低于对照组[(1.07±0.28)、(1.04±0.30)、(1.07±0.24)、(1.22±0.45)分],比较差异有统计学意义(均P<0.05)。治疗后观察组焦虑、抑郁评分[(5.90±2.87)、(5.95±2.94)分]低于对照组[(11.65±3.42)、(12.42±3.2)分],比较差异有统计学意义(均P<0.05)。观察组不良反应总发生率6.82%低于对照组38.64%,比较差异有统计学意义(P<0.05)。结论莫沙必利复合小剂量多塞平治疗PDS-FD可改善患者症状与负面情绪,并减少不良反应。
Objective To observe the clinical efficacy of mosapride combined with low dose of doxepin in the treatment of post PDD type PDS dysfunctional dyspepsia (PDS-FD). Methods 88 patients with PDS-FD treated from June 2015 to June 2016 were randomly divided into observation group and control group, 44 cases in each group. The control group was treated with mosapride alone, and the observation group was given mosapride Compound small dose of doxepin treatment, were treated for 4 weeks. The symptoms of both groups were scored after treatment. Before and after treatment, Hamilton anxiety scale (HAMA) and Hamilton’s depression scale (HAMD) were used to evaluate the degree of anxiety and depression. Insomnia, dizziness, rash As well as adverse reactions such as diarrhea. Measurement data comparison with t test, count the amount of data compared with the χ2 test, P <0.05 for the difference was statistically significant. Results After treatment, the scores of postprandial belching, upper abdominal burning sensation, postprandial fullness and upper abdominal pain score [(0.42 ± 0.02), (0.41 ± 0.01), (0.15 ± 0.06), (0.39 ± 0.02) (1.07 ± 0.28), (1.04 ± 0.30), (1.07 ± 0.24) and (1.22 ± 0.45) points in the control group, respectively. There was significant difference between the two groups (all P <0.05). The scores of anxiety and depression in the observation group after treatment were significantly lower than those in the control group [(5.90 ± 2.87), (5.95 ± 2.94) points [(11.65 ± 3.42), (12.42 ± 3.2) points respectively] <0.05). The total incidence of adverse reactions in the observation group was 6.82% lower than that in the control group (38.64%), with significant difference (P <0.05). Conclusion Mosapride combined with low dose of doxepin in the treatment of PDS-FD can improve the symptoms and negative emotions of patients and reduce adverse reactions.